Actively Recruiting
Randomized Double-Blind Placebo-Controlled Trial of NG004 Antibody in Acute Incomplete Cervical Spinal Cord Injury
Led by NovaGo Therapeutics AG · Updated on 2026-10-23
120
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the human monoclonal antibody NG004 in patients with acute traumatic incomplete cervical spinal cord injury SCI. This randomized, double-blind, placebo-controlled, multicenter Phase 1 trial aims to assess the safety, tolerability, pharmacokinetics, and effects on motor function and daily life functioning of NG004 compared to placebo. The study focuses on patients who have sustained an incomplete cervical SCI within 4 to 28 days prior to enrollment. Participants receive repeated intrathecal injections of either NG004 or placebo within 30 days. This treatment period involves carefully controlled administration of the study drug or placebo directly into the spinal fluid. The trial includes two groups one receiving NG004 and the other receiving placebo, allowing comparison of the effects on neurological recovery and daily functioning. During the trial, participants undergo evaluations of adverse events and drug reactions from treatment start up to 6 months. Motor function changes are measured using the International Standards for Neurological Classification of Spinal Cord Injury protocol, and daily life independence is assessed with the Spinal Cord Independence Measure at 6 months. Safety monitoring and drug concentration measurements in serum and cerebrospinal fluid are performed throughout this period to understand the treatments impact and tolerability.
CONDITIONS
Brief Title
NG004 in Incomplete Spinal Cord Injury Patients
Research Team
D
Director of Clinical Research
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here